Update of 19 September 2016: The shortage affecting Taxotere has been resolved and the below information and recommendations
ve d
which were issued during the shortage no longer apply.
9 June 2016 EMA/403928/2016 Rev. 1
Shortage of Taxotere (docetaxel)
ol
concentrate for solution for infusion vial (20mg / 1 ml and 80mg / 4ml) Indication
Taxotere is used to treat the following cancers: breast cancer,
re s
non-small-cell lung, prostate cancer, gastric adenocarcinoma (a type of stomach cancer), and head and neck cancer.
Reason for shortage
A failure in the filling process at a manufacturing site in Germany has led to Taxotere vials being up to 5 % overconcentrated. The vials contain the same total amount of active substance but in a smaller volume. Sanofi on behalf of
e
the marketing authorisation holder for Taxotere, has therefore
ta g
initiated a recall (see list of batches below) of affected batches. Some of the vials released to the market may have already been used. There is a small risk that patients who have received the affected vials may have received more docetaxel than was intended.
Sh
or
As a consequence of the recall Taxotere 20mg/1 ml and 80 mg/4ml concentrate for solution for infusion may become unavailable in some EU member states. Normal supply is expected to resume on 19 August 2016. Table 1. Recalled batches Vial size
Shortage of Taxotere (docetaxel) concentrate for solution for infusion vial (20mg / 1 ml and 80mg / 4ml) Member States affected 1
Temporary supply disruption may occur in the following EU Member States: France, Ireland, Italy and Spain.
Information to healthcare professionals
•
Batches of Taxotere 20 mg/1ml and 80 mg/4ml concentrate for solution for infusion vial have been recalled in some EU member states due to a failure in the manufacturing process which has resulted in vials being up to 5% over-concentrated. This means that the vials
ve d
contain the total amount of docetaxel in a smaller volume. There is a small risk that patients who have received the
affected vials received an overdose which could lead to an increase in severity and frequency of known adverse events.
Healthcare providers should carefully monitor all patients
ol
•
who have received the affected vials for signs of toxicity and treat these as appropriate. Any suspected adverse
re s
reactions should be reported to the national competent authority.
•
As a consequence of the recall, Taxotere 20 mg/1ml and 80 mg/4ml concentrate for solution for infusion may become unavailable in some EU member states and patients may have to be switched to an alternative
e
docetaxel-containing medicine.
•
Additional advice may be available from the national
ta g
competent authority.
Information to patients
•
Some batches of Taxotere have been recalled in EU member states due to a problem in the manufacturing process which could have led to vials being too
Sh
or
concentrated.
•
There is a small risk that patients who have received the affected vials received too much of the medicine which could increase their risk of side effects.
•
In case you have received any of the affected vials your doctor will monitor you closely for any side effects and treat you as needed. As a consequence of the recall, Taxotere 20mg/1 ml and 80 mg/4ml concentrate for solution for infusion may become unavailable. As other docetaxel-containing medicines are available your doctor will switch you to an alternative docetaxel-containing medicine if needed.
1
This information may change. For accurate information about the status of a medicine shortage in a particular Member State the national competent authority should be contacted.
Shortage of Taxotere (docetaxel) EMA/403928/2016 Rev. 1
Page 2/3
Shortage of Taxotere (docetaxel) concentrate for solution for infusion vial (20mg / 1 ml and 80mg / 4ml) •
Patients who get any side effects should talk to their doctor or pharmacist.
•
Patients who have any questions should speak to their national competent authority.
•
Additional advice may be available from the national
Sh
or
ta g
e
re s
ol
ve d
competent authority.
Shortage of Taxotere (docetaxel) EMA/403928/2016 Rev. 1
Shortage of Taxotere (docetaxel) - European Medicines Agency
Jun 9, 2016 - Send a question via our website www.ema.europa.eu/contact ... Healthcare providers should carefully monitor all patients who have received ...
Apr 28, 2017 - 2. The United Kingdom will then become a 'third country'. 3. Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. In view of the considerable uncertainties, in parti
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. ⢠Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. ⢠Feraccru (ferr
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...
The new EudraVigilance system and the electronic reporting of individual case ... the ISO/ICH E2B(R3) format: hands-on training course - October 2017 ... granted a conditional marketing authorisation on the basis of less complete clinical data ...
4 days ago - EMA/CAT/426129/2018. Page 2/17. Table of contents. 1. Introduction. 5. 1.1. Welcome and declarations of interest of members, alternates and ...
Sep 8, 2016 - 3-year report on Pharmacovigilance activities. Helen Lee, European Commission. â¢. Scanning the horizon for 2016 â 2018. Peter Arlett, EMA.
PCWP and HCPWP joint meeting - Sept 2016 - meeting documents. ⢠Workshop on identifying opportunities for 'big data' in medicines development and ...
Used for the management of hypovolaemia (low blood volume) caused by acute (sudden) blood loss .... EMA's Business Continuity Plan for Brexit published.
On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to enter our industry lounge, which you are welcome to utilise during your visit. The industry loung
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a ... Withdrawal of applications for new medicines .... fifth annual regulatory conference on optimising the development of advanced therapies to.
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to ...
the following public service principles for the EU civil service drawn up by the ... takes into account the experience of the EU network of regulatory agencies ..... 3 The European Medicines Agency Policy on access to documents (related to ...
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.
Jun 18, 2018 - 27. 7.8.1. List of all applications submitted/expected and the COMP coordinatorship distribution of .... 5,10-dihydrodibenzo[b,e][1,4] diazepin-11-one, EMA/OD/031/10 Glutathione-pegylated ...... Abbreviations / Acronyms.
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.
European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 13 September 2017. EMA/727763/2017. Human Medicines Evaluation Division. List of nationally authorised medicinal products. Active substance(s): dexlansop